Gelonghui, January 29丨Longjin Pharmaceutical (002750.SZ) announced its 2023 annual results forecast. Net profit loss attributable to shareholders of listed companies during the reporting period was 63 million yuan to 82 million yuan, loss of 56,165 million yuan for the same period of the previous year; net profit loss after deducting non-recurring profit and loss of 73 million yuan to 92 million yuan, loss of 57.344 million yuan for the same period last year; basic earnings loss per share of 0.1,573 yuan/share to 0.2047 yuan/share; operating income of 81 million yuan to 99 million yuan per share After-sales Revenue of 75 million yuan to 93 million yuan.

During the reporting period, as centralized procurement of proprietary Chinese medicines continued to be implemented, non-harvesting provinces gradually implemented collection price linkage policies, and the continued impact of policies such as medical insurance payment restrictions, the average unit price of the company's core product injectable dengzhanhuacin declined, and sales volume also decreased compared to the same period last year, so the company's operating income decreased. At the same time, the company continued to invest in R&D expenses, cash management investment income decreased year-on-year, and asset impairment losses had a significant impact, leading to an increase in losses in the current period.